Thyrocare Technologies Share Price
Free Demat with Zero AMC*
+ Free 1st Year AMC
Summary
The stock has recorded a trading volume of 66,332 shares,. Its Average Traded Price (ATP) is ₹549.57, while the Last Traded Quantity at the Last Traded Price (LTQ@LTP) is 1 @ ₹549.25.
Thyrocare Technologies has an upper circuit limit of ₹657.95 and a lower circuit limit of ₹438.65. The total value traded stands at ₹3.65 CR, and the delivery percentage for the day is 70.4%.
The stock is currently traded with a market lot size of 1. Thyrocare Technologies also offers a dividend yield of 2.55%.
Thyrocare Technologies Share Price Chart
Thyrocare Technologies Share Key Metrics
Volume
66332.00
Market Cap
8727.03 CR
LTQ@LTP
1@549.25
ATP
549.57
Var Margin
19.64 %
Circuit Range
438.65-657.95
Delivery %
70.4 %
Value
3.65 CR
ASM/GSM
No
Market Lot
1
Thyrocare Technologies Resistance and Support
Pivot 553.02
Resistance
First Resistance
559.44
Second Resistance
570.57
Third Resistance
576.99
Support
First Support
541.89
Second Support
535.47
Third Support
524.34
Thyrocare Technologies Shareholding Pattern
View More- 2018-19
- 2019-20
- 2020-21
- 2021-22
- 2022-23
- 2023-24
- 2024-25
- 2025-26
- 2026-27
Total Promoters
Thyrocare Technologies Corporate Actions
| Date | Agenda |
|---|---|
| 2026-07-23 | Quarterly Results |
| 2026-05-07 | Audited Results & Final Dividend |
| 2026-01-28 | Quarterly Results |
| 2025-10-14 | Qtr Results |
| 2025-07-23 | Quarterly Results |
| 2025-04-23 | Audited Results & Final Dividend |
| 2025-01-23 | Quarterly Results |
| 2024-10-23 | Quarterly Results |
| Ex Date | Record Date | |
|---|---|---|
| 2026-06-23 | 2026-06-23 | View More |
| Bonus Date | Record Date | |
|---|---|---|
| 2025-10-14 | 2025-11-28 | View More |
Thyrocare Technologies News
Thyrocare Technologies Ltd - 539871 - Sale Of The Entire Shareholding Held By The Company In Nueclear Healthcare Limited (A Material Wholly Owned Subsidiary), Subject To The Approval Of The Shareholders Of The Company
Thyrocare Technologies' board approved the divestment of its wholly-owned subsidiary, Nueclear Healthcare Limited (NHL), for Rs. 141.40 crore. The move allows the company to exit the radiology business and focus on its core pathology operations.
Sep 21 2026 15:06:23
Thyrocare Technologies Ltd - 539871 - Announcement under Regulation 30 (LODR)-Acquisition
Thyrocare Technologies' Board approved acquiring 42,500 Compulsorily Convertible Preference Shares (CCPS) of Trovera Healthcare Private Limited for Rs. 59.5 crore. This acquisition is part of the consideration for divesting its entire 100% shareholding in Nueclear Healthcare Limited, its radiology business.
Sep 21 2026 15:02:22
Thyrocare Technologies Ltd - 539871 - Outcome Of The Board Meeting Held On Monday, September 21, 2026
Thyrocare Technologies' board approved the divestment of its wholly-owned subsidiary, Nueclear Healthcare Limited (NHL), for Rs. 141.40 crore. The move allows the company to exit the radiology business and focus on its core pathology operations.
Sep 21 2026 14:57:05
Thyrocare Technologies Ltd - 539871 - Revised Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
API Holdings, the successor entity to erstwhile promoter Docon Technologies, released a pledge on 7.94 crore equity shares of Thyrocare Technologies. This represents 49.93% of Thyrocare's total share capital, previously securing NCDs worth Rs.1,050 crore which were repaid.
Sep 09 2026 12:22:42
Thyrocare Technologies Ltd - 539871 - Disclosures under Reg. 10(6) of SEBI (SAST) Regulations, 2011
API Holdings acquired a 51.02% stake in Thyrocare Technologies Limited by operation of law following the NCLT-sanctioned amalgamation of Docon Technologies Private Limited with API Holdings. The transaction was effective September 03, 2026.
Sep 04 2026 16:30:27
Thyrocare Technologies Ltd - 539871 - Communication Received From API Holdings Limited Regarding Approval Of Scheme Of Amalgamation Of Docon Technologies Private Limited With API Holdings Limited
NCLT, Mumbai Bench, has sanctioned the Scheme of Amalgamation of Docon Technologies with API Holdings. Docon's 51.02% shareholding in Thyrocare will be transferred to API, with no change in the aggregate promoter group stake. This is an internal restructuring within the promoter group.
Sep 01 2026 17:21:22
Thyrocare Technologies Management
| Name | Position |
|---|---|
| Brijesh Kumar | Company Secretary & Compliance Officer |
| Rahul Guha | Chairman, Managing Director & Chief Executive Officer |
Thyrocare Technologies Similar Stocks
Blue Jet Healthcare Ltd.
563.40
6.10 (1.09%)
Yatharth Hospital & Trauma Care Services Ltd.
1105.90
5.50 (0.50%)
Viyash Scientific Ltd.
240.40
-0.60 (0.25%)
Healthcare Global Enterprises Ltd.
700.60
9.40 (1.36%)
Suven Life Sciences Ltd.
328.85
7.20 (2.24%)
Jupiter Life Line Hospitals Ltd.
258.35
-5.50 (2.08%)
Procter & Gamble Health Ltd.
5809.00
409.50 (7.58%)
Aarti Pharmalabs Ltd.
949.45
35.45 (3.88%)
Bliss GVS Pharma Ltd.
716.00
-21.65 (2.93%)
Innova Captab Ltd.
1270.00
-1.20 (0.09%)
Thyrocare Technologies FAQs
Open Your Free
Demat Account Now!
AMC for First Year
Auto Square Off Charges
+ Free 1st Year AMC
13 Lakh+ Clients
Expert-Backed
Premium Tools

Open Your Free
Demat Account Now!
AMC For First Year
Account Opening Fee
+ Free 1st Year AMC
13 Lakh+ Clients
Expert-Backed
Premium Tools
Invest in THYROCARE
Account Opening Fee AMC for 1st Year Auto Square Off Charges Call & Trade
+ Free 1st Year AMC